Detalhe da pesquisa
1.
Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.
Br J Haematol;
2024 Apr 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38685577
2.
RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.
Cancer Lett;
580: 216486, 2024 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37984724
3.
Scutellarein regulates the PTEN/AKT/NFκB signaling pathway to reduce pirarubicin related liver inflammation.
Int J Mol Med;
52(1)2023 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37232353
4.
Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.
Hematology;
28(1): 2187972, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36920065
5.
Does proton pump inhibitors use increase risk of digestive tumors?: A 2-sample Mendelian randomization study.
Medicine (Baltimore);
102(45): e36085, 2023 Nov 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37960715
6.
Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity.
ACS Omega;
8(1): 1693-1701, 2023 Jan 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36643473
7.
Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma.
Cancer Lett;
565: 216218, 2023 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37149018
8.
Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma.
Life Sci;
333: 122157, 2023 Nov 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37805164
9.
A novel immune prognostic model of non-M3 acute myeloid leukemia.
Am J Transl Res;
14(8): 5308-5325, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36105048
10.
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
JCI Insight;
7(19)2022 10 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36040812
11.
ALCAM regulates multiple myeloma chemoresistant side population.
Cell Death Dis;
13(2): 136, 2022 02 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35145058
12.
ZWINT is a Promising Therapeutic Biomarker Associated with the Immune Microenvironment of Hepatocellular Carcinoma.
Int J Gen Med;
14: 7487-7501, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34744456
13.
Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis.
Front Genet;
12: 764245, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34777483
14.
Comprehensive Analysis of LPCATs Highlights the Prognostic and Immunological Values of LPCAT1/4 in Hepatocellular Carcinoma.
Int J Gen Med;
14: 9117-9130, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34876845
15.
Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma.
Aging (Albany NY);
13(8): 11786-11807, 2021 04 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33878734
16.
Minimal residual disease in multiple myeloma: current status.
Biomark Res;
9(1): 75, 2021 Oct 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34649622
17.
[Histological changes in the livers of chronic hepatitis B patients with persistently normal serum alanine transaminase levels].
Zhonghua Gan Zang Bing Za Zhi;
15(12): 881-5, 2007 Dec.
Artigo
em Zh
| MEDLINE
| ID: mdl-18171518